T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
New therapies for hepatitis infection
TL;DR: Estimates suggest that approximately 200 million individuals are infected with HBV or HCV without HIV co-infection, and that diagnosis rates are increasing, according to World Health Organization estimates.
Journal ArticleDOI
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
Toni K. Choueiri,Laurence Albiges,Piotr Tomczak,Cristina Sáez,Martin H. Voss,Guillermo Velasco,Jad Chahoud,Giuseppe Procopio,Hakim Mahammedi,Friedemann Zengerling,Chang Gon Kim,Guillaume Bergthold,Bo Liu,Mahrukh Huseni,Christian Scheffold,Thomas Powles,Sumanta K. Pal +16 more
TL;DR: In this paper , the authors evaluated anti-PD-L1 atezolizumab (atezo) + cabo vs cabo alone in patients with metastatic RCC that progressed during or after prior ICI treatment and is the first phase 3 randomized trial to test the benefit of ICI rechallenge by direct addition to a control arm.
Journal ArticleDOI
Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.
Nick van Dijk,Alfonso Gomez De Liano Lista,Bernadett Szabados,Thomas Powles,Michiel S. van der Heijden +4 more
Journal ArticleDOI
Reply to M. Horiguchi et al.
Journal ArticleDOI
Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma
Bernadett Szabados,S Duncan,Julia Choy,Francesca Jackson-Spence,C. Toms,G. Trevisan,Daniel M. Berney,Thomas Powles,C Ackerman +8 more
TL;DR: AR expression is a predictor of poor outcome and presents a targetable alteration in patients with mUC.